Revenue
2018
2019
2020
2021
2022
2023
2024
2025
LIGAND PHARMACEUTICALS INC (LGND)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $268.1M | $167.1M | $131.3M | $196.2M | $241.5M | $163.6M | $120.3M | $251.5M | $141.1M | $109.0M | $71.9M | $64.5M | $49.0M | $31.4M | $30.0M | $23.5M | $38.9M |
| Research & development | $81.2M | $21.4M | $24.5M | $36.1M | $32.1M | $40.5M | $55.9M | $27.9M | $26.9M | $21.2M | $11.0M | $9.7M | $9.3M | $10.8M | $10.3M | $22.1M | $39.9M |
| Operating expenses | $227.1M | $189.7M | $121.5M | $193.2M | $137.7M | $143.2M | $126.0M | $87.7M | $73.0M | $65.1M | $44.6M | $44.9M | $34.0M | $31.2M | $32.6M | $54.5M | $70.8M |
| Operating income | $41.0M | −$22.6M | $11.9M | $3.0M | $103.9M | $37.5M | $807.1M | $163.7M | $68.1M | $43.9M | $27.3M | $19.6M | $14.9M | $193,000 | −$878,000 | −$29.3M | −$10.0M |
| EBITDAderived | $74.8M | $12.6M | $48.5M | $54.6M | $154.9M | $63.2M | $825.4M | $176.5M | $79.0M | $55.2M | $30.0M | $22.3M | $17.6M | $2.9M | $1.9M | −$27.1M | −$5.3M |
| Net income | $124.5M | −$4.0M | $52.2M | −$33.4M | $57.1M | −$3.0M | $629.3M | $143.3M | $12.6M | −$1.6M | $229.8M | $12.0M | $11.4M | −$527,000 | $9.7M | −$10.4M | −$1.9M |
| Basic EPSper diluted share | $6.44 | -$0.22 | $3.02 | -$1.98 | $3.44 | -$0.18 | $33.13 | $6.77 | $0.60 | -$0.08 | $11.61 | $0.59 | $0.56 | -$0.03 | $0.49 | -$0.53 | -$0.10 |
| Diluted EPSper diluted share | $6.13 | -$0.22 | $2.94 | -$1.98 | $3.31 | -$0.18 | $31.85 | $5.96 | $0.53 | -$0.08 | $10.83 | $0.56 | $0.55 | -$0.03 | $0.49 | -$0.53 | -$0.10 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Jun 16, 2026Form 4 | Sabba Stephen LDirector | SellCommon Stock | 2.1K | $254.00 | $544.8K | 33.6K |
| Jun 12, 2026Form 4 | Haas JasonDirector | SellCommon Stock | 3.5K | $256.08 | $886.3K | 5.0K |
| Jun 12, 2026Form 4 | Haas JasonDirector | SellCommon Stock | 3.0K | $255.01 | $765.0K | 8.4K |
| Jun 11, 2026Form 4 | Aryeh JasonDirector | SellCommon Stock | 4.5K | $250.00 | $1.13M | 102.6K |
| Jun 10, 2026Form 4 | Aryeh JasonDirector | SellCommon Stock | 500 | $250.00 | $125.0K | 107.1K |